Navigation Links
Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
Date:12/20/2013

NEW YORK, December 20, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Dyax Corp. (NASDAQ: DYAX), IPC The Hospitalist Company, Inc. (NASDAQ: IPCM), Array BioPharma Inc. (NASDAQ: ARRY), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), and Wright Medical Group, Inc. (NASDAQ: WMGI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Dyax Corp. Research Report

On December 9, 2013, Dyax Corp. (Dyax) announced positive results from both preclinical studies of the investigational product DX-2930 and its biomarker assay program for detection of contact system activation of plasma kallikrein (pKal) at American Society of Hematology Annual Meeting and Exposition on December 7-10, 2013. The Company stated that DX-2930 is currently being studied in a placebo-controlled, dose-escalation Phase 1 trial in healthy subjects, with results expected in Q1 2014. Burt Adelman, M.D., Chief Medical Officer and Executive Vice President of Research and Development at Dyax, commented, "A key finding from ex-vivo experimental studies is the observation that DX-2930 and ecallantide can be compared as inhibitors of pKal. The successful development of ecallantide has clearly demonstrated that pKal is a valid target. We are leveraging this knowledge to develop DX-2930." The Full Research Report on Dyax Corp. - including full detailed breakdown, analyst ratings and price tar
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
2. According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients
3. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
4. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
5. Upsher-Smith Debuts Positive Results From Global Phase 3 Study Evaluating USL255 (extended-release topiramate) In Epilepsy Patients With Refractory Partial-Onset Seizures
6. Annual General Meeting Schedules, New Drug Applications, Positive Study Results, Conference Participations, and Secondary Offerings - Research Report on Mindray, AcelRx, Merrimack, ZELTIQ, and Clovis
7. Dividends, Recognitions, Positive Opinions, Share Repurchase Programs, and Award Programs - Research Report on BD, Sanofi, GSK, Agilent Technologies, and Align Technology
8. According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population
9. Positive FDA Meeting Confirms BDSI Phase 3 Program for Clonidine Topical Gel for Treatment of Painful Diabetic Neuropathy
10. Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer
11. According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... "the company") announced today that the company,s board of directors ... 31 to June 30. Accordingly, DelMar will file a Transition ... Jeffrey Bacha , president and CEO of DelMar stated, ... in achieving our goal of obtaining a senior exchange listing ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
(Date:7/24/2014)... Talyst, a market leader in pharmacy automation, ... State Veterans Homes (NASVH) Summer Conference in ... NASVH is to ensure that each and every eligible ... care and respect which they have earned by their ... Remote Dispensing System, Talyst can help State Veterans Homes ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2
... 8, 2010 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., ... company that develops, manufactures and sells patented biopharmaceutical, ... pharmaceuticals, today announced that the senior management will ... quarter of fiscal year 2011 ending September 30, ...
... Md., Nov. 8, 2010 Substandard and counterfeit versions ... locations across Ghana by the Medicines Quality Monitoring surveillance ... Board (FDB) in collaboration with the U.S. Pharmacopeial Convention ... the program samples antimalarials across the public and private ...
Cached Medicine Technology:Tianyin Pharmaceutical Co., Inc. to Host First Quarter of Fiscal Year 2011 Earnings Conference Call on Thursday, November 11, 2010 at 9:00 a.m. ET 2Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 2Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 3
(Date:7/24/2014)... Members of the Iowa State Board of Health ... of Sales at OutcomesMTM, as their Chairperson. Wolnerman said he ... and that his peers chose to keep him in this ... I can for the citizens of Iowa,” Wolnerman said. “As ... a special insight to concerns and issues related to the ...
(Date:7/24/2014)... BOSTON -- A new study has shown that it is ... by measuring the short-term effects of that same exposure. The ... , will make it possible to develop simpler and cheaper ... , Despite an overall decrease in incidence of ... be diagnosed with the disease in their lifetime, and around ...
(Date:7/24/2014)... PHILADELPHAA rare procedure occasionally performed during Jewish circumcisions that ... herpes simplex virus type 1 (HSV-1) transmissions documented ... review conducted by Penn Medicine researchers and published ... Disease Society found. The reviewers, from Penn,s ... cases in New York, Canada and Israel. , The ...
(Date:7/24/2014)... the Human Papillomavirus Vaccination (HPV) even after becoming ... test results than those who were never vaccinated. ... Transmitted Diseases . , Researchers from Boston ... Medicine conducted a cross-sectional study of 235 women ... testing. HPV status and demographic and behavioral characteristics ...
(Date:7/24/2014)... According to market research report "3D ... Forecasts and Analysis - 2018", the 3D mapping ... $7.7 billion by 2018 at a CAGR of ... data tables and 30 figures spread through 222 ... Global Advancements, Business Models, Technology Roadmap, Forecasts and ...
Breaking Medicine News(10 mins):Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Researchers discover new way to determine cancer risk of chemicals 2Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4
... Effect was especially strong for estrogen-sensitive tumor types, study ... consumed even in small amounts, increases the risk of ... cancer, a new study shows. , The findings, expected ... the American Association for Cancer Research, in San Diego, ...
... (p. 46). Senior Editor David J. Jefferson writes,about the ... Ulysses S.,Grant High School, class of ,82 as part ... former classmates, Jefferson tells the,stories of those who lived ... the first for which divorce was just another part ...
... attacks in their tracks , , SATURDAY, April 12 (HealthDay ... for millions of Americans. , With a bit ... their suffering or perhaps even avoid it altogether, according ... of allergy and clinical immunology at the Saint Louis University ...
... Care, MILLBRAE, Calif., April 11 Healthcare ... second strike at,the facility in two months, in ... workers, proposals to improve care., The three-day ... on Tuesday, April 15.,Caregivers launched a previous, 24-hour ...
... paid but more upset when they owned stock , , ... clinical studies aren,t overly concerned if researchers have financial ... a U.S. study. , "Though peoples, willingness to take ... substantially based on the types of financial disclosures, and ...
... Puerto Ricans have higher rates of depression than other ... new study by researchers at Hebrew SeniorLifes Institute for ... Ricans, who make up 11 percent of the Hispanics ... depression, compared to Mexican Americans, Cuban Americans, and Hispanics ...
Cached Medicine News:Health News:Drinking May Raise Breast Cancer Risk 2Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 2Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 3Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 4Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 5Health News:Spring and Pollen Are in the Air 2Health News:Clinical Trial Volunteers Uneasy About Some Financial Ties 2Health News:Researchers find disparities in depression among older Hispanics in US 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: